Physician profile
Erum Shahab
NPI 1669434049
$15,811.32
in general payments reported to CMS, 2019-2025
27 companies · $1,590 in 2025
The $1,590 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,203 · 2020: $2,182 · 2021: $3,036 · 2022: $2,696 · 2023: $2,944 · 2024: $2,160 · 2025: $1,590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,680 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,679.85 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $1,907.09 | 2019-2025 | Wellbutrin, Aplenzin |
| Abbvie INC. | $1,742.35 | 2021-2025 | Vraylar |
| Sunovion Pharmaceuticals INC. | $1,553.00 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $1,528.99 | 2019-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $1,419.00 | 2019-2025 | Spravato, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,294.68 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $1,067.66 | 2022-2025 | Austedo Xr, Austedo, Uzedy |
| Lundbeck LLC | $862.25 | 2019-2025 | Rexulti |
| Alkermes, INC. | $774.94 | 2020-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $656.85 | 2020-2025 | Ingrezza |
| Allergan, INC. | $606.85 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $538.12 | 2020-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Avanir Pharmaceuticals, INC. | $353.42 | 2020-2022 | |
| Axsome Therapeutics, INC. | $346.91 | 2022-2025 | Auvelity |
| Mdd US Operations, LLC | $204.14 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Uswm, LLC | $164.41 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $157.06 | 2024-2025 | Cobenfy |
| Eisai INC. | $139.81 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $123.17 | 2023-2024 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $105.09 | 2019-2022 | |
| Neuronetics, INC. | $86.09 | 2019-2020 | |
| Luye Pharma (USA) LTD. | $66.84 | 2025 | Erzofri Extended-Release |
| Shire North American Group INC | $43.40 | 2019 | |
| Azurity Pharmaceuticals, INC. | $24.01 | 2024 | |
| Pfizer INC. | $16.76 | 2019 | |
| Merck Sharp & Dohme LLC | $16.69 | 2019 | |
| Noven Therapeutics, LLC | $11.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erum Shahab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.